{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:22Z","timestamp":1794047482066,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells within the bone marrow. It is characterized by a highly heterogeneous clinical and molecular background, supported by severe genomic alterations. Important de-regulation of long non-coding RNA (lncRNA) expression, which can influence progression and therapy resistance, has been reported in MM patients. NEAT1 is a lncRNA essential for nuclear paraspeckles and is involved in the regulation of gene expression. We showed that NEAT1 supports MM proliferation, making this lncRNA an attractive therapeutic candidate. Here, we used a combinatorial strategy integrating transcriptomic and computational approaches with functional high-throughput drug screening to identify compounds that synergize with NEAT1 inhibition in restraining MM cell growth. AURKA inhibitors were identified as top-scoring drugs in these analyses. We showed that the combination of NEAT1 silencing and AURKA inhibitors in MM profoundly impairs microtubule organization and mitotic spindle assembly, finally leading to cell death. Analysis of the large publicly available CoMMpass dataset showed that, in MM patients, AURKA expression is strongly associated with reduced progression-free survival (P&lt;0.0001) and overall survival (P&lt;0.0001) probabilities and patients with high levels of expression of both NEAT1 and AURKA have a worse clinical outcome. Finally, using RNA-sequencing data from NEAT1 knockdown MM cells, we identified the AURKA allosteric regulator TPX2 as a new NEAT1 target in MM and as a mediator of the interplay between AURKA and NEAT1, therefore providing a possible explanation for the synergistic activity observed upon their combinatorial inhibition.<\/jats:p>","DOI":"10.3324\/haematol.2024.285470","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T03:38:56Z","timestamp":1720669136000},"page":"4040-4055","source":"Crossref","is-referenced-by-count":4,"title":["Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Noemi","family":"Puccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Manzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Mereu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Torricelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Ronchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Cumerlato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Craparotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Rito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Traini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Manicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fragliasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Torrente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Taiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciarrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Piva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"70069","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-1060.","DOI":"10.1056\/NEJMra1011442"},{"key":"70070","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cance J Clin. 2016; 66(1):7-30.","DOI":"10.3322\/caac.21332"},{"key":"70071","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567.","DOI":"10.1002\/ajh.25791"},{"key":"70072","doi-asserted-by":"crossref","unstructured":"Egan JB, Shi CX, Tembe W. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.","DOI":"10.1182\/blood-2012-01-405977"},{"key":"70073","doi-asserted-by":"crossref","unstructured":"Quinn JJ, Chang H. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016; 17(1):47-62.","DOI":"10.1038\/nrg.2015.10"},{"key":"70074","doi-asserted-by":"crossref","unstructured":"Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-914.","DOI":"10.1016\/j.molcel.2011.08.018"},{"key":"70075","doi-asserted-by":"crossref","unstructured":"Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019; 8(9):1015.","DOI":"10.3390\/cells8091015"},{"key":"70076","doi-asserted-by":"crossref","unstructured":"Ronchetti D, Agnelli L, Taiana E. Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget. 2016; 7(12):14814-14830.","DOI":"10.18632\/oncotarget.7442"},{"key":"70077","doi-asserted-by":"crossref","unstructured":"Taiana E, Gallo Cantafio ME, Favasuli VK. Genomic instability in multiple myeloma: a \u201cnon-coding RNA\u201d perspective. Cancers (Basel). 2021; 13(9):2127.","DOI":"10.3390\/cancers13092127"},{"key":"70078","doi-asserted-by":"crossref","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021; 22(2):96-118.","DOI":"10.1038\/s41580-020-00315-9"},{"key":"70079","doi-asserted-by":"crossref","unstructured":"Guru SC, Agarwal SK, Manickam P. A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res. 1997; 7(7):725-735.","DOI":"10.1101\/gr.7.7.725"},{"key":"70080","doi-asserted-by":"crossref","unstructured":"Naganuma T, Nakagawa S, Tanigawa A, Sasaki YF, Goshima N, Hirose T. Alternative 3\u2019-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. EMBO J. 2012; 31(20):4020-4034.","DOI":"10.1038\/emboj.2012.251"},{"key":"70081","doi-asserted-by":"crossref","unstructured":"Taiana E, Ronchetti D, Favasuli V. Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica. 2019; 104(2):e72-e76.","DOI":"10.3324\/haematol.2018.201301"},{"key":"70082","doi-asserted-by":"crossref","unstructured":"Clemson CM, Hutchinson JN, Sara SA. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 2009; 33(6):717-726.","DOI":"10.1016\/j.molcel.2009.01.026"},{"key":"70083","doi-asserted-by":"crossref","unstructured":"Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell. 2009; 35(4):467-478.","DOI":"10.1016\/j.molcel.2009.06.027"},{"key":"70084","doi-asserted-by":"crossref","unstructured":"Hirose T, Virnicchi G, Tanigawa A. NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies. Mol Biol Cell. 2014; 25(1):169-183.","DOI":"10.1091\/mbc.e13-09-0558"},{"key":"70085","doi-asserted-by":"crossref","unstructured":"Jiang L, Shao C, Wu QJ. NEAT1 scaffolds RNA-binding proteins and the microprocessor to globally enhance pri-miRNA processing. Nat Struct Mol Biol. 2017; 24(10):816-824.","DOI":"10.1038\/nsmb.3455"},{"key":"70086","doi-asserted-by":"crossref","unstructured":"Li R, Harvey AR, Hodgetts SI, Fox AH. Functional dissection of NEAT1 using genome editing reveals substantial localization of the NEAT1_1 isoform outside paraspeckles. RNA. 2017; 23(6):872-881.","DOI":"10.1261\/rna.059477.116"},{"key":"70087","doi-asserted-by":"crossref","unstructured":"Taiana E, Favasuli V, Ronchetti D. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2020; 34(1):234-244.","DOI":"10.1038\/s41375-019-0542-5"},{"key":"70088","doi-asserted-by":"crossref","unstructured":"Taiana E, Bandini C, Favasuli VK. Activation of lncRNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Haematologica. 2020; 108(1):219-233.","DOI":"10.3324\/haematol.2022.281167"},{"key":"70089","doi-asserted-by":"crossref","unstructured":"Bandini C, Mereu E, Paradzik T. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol. 2023; 12(1):71.","DOI":"10.1186\/s40164-023-00434-x"},{"key":"70090","doi-asserted-by":"crossref","unstructured":"Mereu E, Abbo D, Paradzik T. Euchromatic histone lysine methyltransferase 2 inhibition enhances carfilzomib sensitivity and overcomes drug resistance in multiple myeloma cell lines. Cancers (Basel). 2023; 15(8):2199.","DOI":"10.3390\/cancers15082199"},{"key":"70091","doi-asserted-by":"crossref","unstructured":"Rosenthal A, Kumar S, Hofmeister C. A phase Ib study of the combination of the Aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma. Br J Haematol. 2016; 174(2):323-325.","DOI":"10.1111\/bjh.13765"},{"key":"70092","doi-asserted-by":"crossref","unstructured":"Metselaar DS, du Chatinier A, Meel MH. AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. iScience. 2022; 25(6):104398.","DOI":"10.1016\/j.isci.2022.104398"},{"key":"70093","doi-asserted-by":"crossref","unstructured":"Fathi AT, Wander SA, Blonquist TM. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017; 102(4):719-727.","DOI":"10.3324\/haematol.2016.158394"},{"key":"70094","doi-asserted-by":"crossref","unstructured":"Kufer TA, Sillj\u00e9 HH, K\u00f6rner R, Gruss OJ, Meraldi P, Nigg EA. TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Bio. 2022; 158(4):617-623.","DOI":"10.1083\/jcb.200204155"},{"key":"70095","doi-asserted-by":"crossref","unstructured":"Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase Aurora A. Curr Biol. 2023; 13(8):691-697.","DOI":"10.1016\/S0960-9822(03)00166-0"},{"key":"70096","doi-asserted-by":"crossref","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015; 2015:341430.","DOI":"10.1155\/2015\/341430"},{"key":"70097","doi-asserted-by":"crossref","unstructured":"Vo JN, Wu YM, Mishler J. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022; 13(1):3750.","DOI":"10.1038\/s41467-022-31430-0"},{"key":"70098","doi-asserted-by":"crossref","unstructured":"Ronchetti D, Agnelli L, Pietrelli A. A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Sci Rep. 2018; 8(1):6557.","DOI":"10.1038\/s41598-018-24701-8"},{"key":"70099","doi-asserted-by":"crossref","unstructured":"Pistoni M, Rossi T, Donati B, Torricelli F, Polano M, Ciarrocchi A. Long noncoding RNA NEAT1 acts as a molecular switch for BRD4 transcriptional activity and mediates repression of BRD4\/ WDR5 target genestranscriptional repression via lncRNA NEAT1\/ BRD4 interaction. Mol Cancer Res. 2021; 19(5):799-811.","DOI":"10.1158\/1541-7786.MCR-20-0324"},{"key":"70100","doi-asserted-by":"crossref","unstructured":"Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12(11):847-865.","DOI":"10.1038\/nrd4140"},{"key":"70101","doi-asserted-by":"crossref","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020; 19(10):673-694.","DOI":"10.1038\/s41573-020-0075-7"},{"key":"70102","doi-asserted-by":"crossref","unstructured":"Xie Y, Zhu S, Zhong M. Inhibition of Aurora kinase A induces necroptosis in pancreatic carcinoma. Gastroenterology. 2017; 153(5):1429-1443.","DOI":"10.1053\/j.gastro.2017.07.036"},{"key":"70103","doi-asserted-by":"crossref","unstructured":"Wang P, Gong Y, Guo T. Activation of Aurora A kinase increases YAP stability via blockage of autophagy. Cell Death Dis. 2019; 10(6):432.","DOI":"10.1038\/s41419-019-1664-4"},{"key":"70104","doi-asserted-by":"crossref","unstructured":"Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017; 8(14):23937-23954.","DOI":"10.18632\/oncotarget.14893"},{"key":"70105","doi-asserted-by":"crossref","unstructured":"Murga-Zamalloa C, Inamdar KV, Wilcox RA. The role of aurora A and polo-like kinases in high-risk lymphomas. Blood Adv. 2019; 3(11):1778-1787.","DOI":"10.1182\/bloodadvances.2019000232"},{"key":"70106","doi-asserted-by":"crossref","unstructured":"Naso FD, Boi D, Ascanelli C. Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer. Oncogene. 2021; 40(23):3917-3928.","DOI":"10.1038\/s41388-021-01766-w"},{"key":"70107","doi-asserted-by":"crossref","unstructured":"Garrido G, Vernos I. Non-centrosomal TPX2-dependent regulation of the Aurora A kinase: functional implications for healthy and pathological cell division. Front Oncol. 2016; 6:88.","DOI":"10.3389\/fonc.2016.00088"},{"key":"70108","doi-asserted-by":"crossref","unstructured":"Mou PK, Yang EJ, Shi C, Ren G, Tao S, Shim JS. Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp Mol Med. 2021; 53(5):835-847.","DOI":"10.1038\/s12276-021-00635-6"},{"key":"70109","doi-asserted-by":"crossref","unstructured":"Hose D, R\u00e8me T, Hielscher T. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011; 96(1):87-95.","DOI":"10.3324\/haematol.2010.030296"},{"key":"70110","doi-asserted-by":"crossref","unstructured":"Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell. 2003; 12(4):851-862.","DOI":"10.1016\/S1097-2765(03)00392-7"},{"key":"70111","doi-asserted-by":"crossref","unstructured":"Levinson NM. The multifaceted allosteric regulation of Aurora kinase A. Biochem J. 2018; 475(12):2025-2042.","DOI":"10.1042\/BCJ20170771"},{"key":"70112","doi-asserted-by":"crossref","unstructured":"Lake EW, Muretta JM, Thompson AR. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. Proc Natl Acad Sci U S A. 2018; 115(51):e11894-E11903.","DOI":"10.1073\/pnas.1811158115"},{"key":"70113","doi-asserted-by":"crossref","unstructured":"Zhao Y, Wang Z, Mao Y. NEAT1 regulates microtubule stabilization via FZD3\/GSK3\u03b2\/P-tau pathway in SH-SY5Y cells and APP\/PS1 mice. Aging (Albany NY). 2020; 12(22):23233-23250.","DOI":"10.18632\/aging.104098"},{"key":"70114","doi-asserted-by":"crossref","unstructured":"Chen D, Wang J, Li Y. LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A. Clin Transl Med. 2023; 9:e1418.","DOI":"10.1002\/ctm2.1418"},{"key":"70115","doi-asserted-by":"crossref","unstructured":"Do TV, Hirst J, Hyter S, Roby KF, Godwin AK. Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget. 2019; 8(31):50376-50392.","DOI":"10.18632\/oncotarget.18970"},{"key":"70116","doi-asserted-by":"crossref","unstructured":"Hose D, R\u00e8me T, Meissner T. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009; 113(18):4331-4340.","DOI":"10.1182\/blood-2008-09-178350"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285470\/77256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285470\/77839","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11681\/77256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:50Z","timestamp":1794046010000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285470","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}